Article info
PDFAcute coronary syndromes
Original article
Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction
- Correspondence to Dr Matthias Schwenkglenks, University of Basel, Institute of Pharmaceutical Medicine (ECPM), Klingelbergstrasse 61, 4056 Basel, Switzerland; m.schwenkglenks{at}unibas.ch
Citation
Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction
Publication history
- Accepted January 5, 2012
- First published February 7, 2012.
Online issue publication
October 25, 2017
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.